Amyloid tau protein and brain structure network

Not Applicable

Recruiting

• Conditions: Mild cognitive impairment or Alzheime's disease; Alzheimer disease, cognitive impairment; D000544

• Registration Number: JPRN-jRCTs031210318
• Lead Sponsor: Matsuda Hiroshi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-09-16
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1) Those who have cognitive impairment suspected of having MCI and early AD based on the diagnostic
criteria of NIA-AA or DSM-5
2) 40 to 90 years old, regardless of gender
3) A person who can obtain written consent from the person or his / her substitute.
4) MRI imaging including 3DT1 weighted image has already been performed within 90 days at the time of obtaining consent.

Exclusion Criteria

1) Those who have gross lesions (brain tumor, cerebral vascular malformation, cortical infarction, etc.) on
brain MRI.
2) Those who have serious complications, or those who have a history of these and are judged by the
investigator and the investigator to be ineligible for this study.
3) In addition, those who are judged by the principal investigator and the investigator to be ineligible for this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1) Quantitative evaluation of amyloid beta protein with 18F-NAV4694 PET<br>2)Quantitative evaluation of tau protein with 18F-MK6240 PET<br>3)Structural network analysis and production of each parametric image from 3D T1WI brain MRI<br>4)Correlation analysis of each structural network parametric image with accumulation of Abeta and tau <br> protein

Secondary Outcome Measures

Name	Time	Method
Safety of 18F-MK6240 and 18F-NAV4694